Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

Schizophrenia Clinical Trial

— ASPIRE  

Official title:

A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00705783
• Other study ID #: 31-07-246
• Status: Completed
• Phase: Phase 3
• First received: June 24, 2008
• Last updated: June 16, 2013
• Start date: July 2008
• Est. completion date: February 2011

Study information

• Verified date: June 2013
• Source: Otsuka Pharmaceutical Development & Commercialization, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the trial was to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia.

The trial was designed into 4 treatment phases. Phase 1 was designed to allow for a patient to be converted from their current antipsychotic treatment to oral non-generic aripiprazole monotherapy (oral conversion phase from 4 to 6 weeks). During Phase 2, the patient was stabilized on oral non-generic aripiprazole monotherapy (oral stabilization phase from a minimum of 4 weeks to a maximum of 12 weeks). Once the patient was stabilized in Phase 2, they entered Phase 3, the single-blind intramuscular (IM) depot aripiprazole stabilization phase. The goal of the phase was to stabilize the patient on the IM depot aripiprazole formulation for a minimum of 12 weeks to a maximum of 36 weeks. When the patient was stabilized, they were eligible to be randomized into the double-blind IM depot maintenance phase (Phase 4). During Phase 4, the patient was assessed for exacerbation of psychotic symptoms and/or impending relapse for up to 52 weeks.

Description:

This was a randomized, double-blind, placebo-controlled study consisting of a screening phase and 4 treatment phases. Eligibility was determined during a screening phase of 2 to 42 days. Patients receiving oral treatment with an antipsychotic other than non-generic aripiprazole entered Phase 1. Patients with a lapse in aripiprazole or other antipsychotic treatment at the time of study entry ("lapse" defined as > 3 consecutive days without medication) entered directly into Phase 2. During Phase 1 (oral conversion), patients were cross-titrated during weekly visits from other antipsychotics to oral non-generic aripiprazole monotherapy over a minimum of 4 weeks and a maximum of 6 weeks. During Phase 2 (a minimum of 4 weeks and a maximum of 12 weeks in duration), patients were assessed bi-weekly and stabilized on an oral dose of aripiprazole ranging from 10 mg to 30 mg daily. After stability criteria were met in Phase 2, patients entered the single-blind aripiprazole intramuscular (IM) depot stabilization phase, Phase 3. In Phase 3, patients were stabilized on aripiprazole IM depot for 12 consecutive weeks. Once the patient met the stability criteria, they were eligible to be randomized into the double-blind phase, Phase 4. Patients were randomized in a 2:1 ratio (aripiprazole IM depot vs placebo IM depot) stratified by region and last aripiprazole IM depot injection dose level in Phase 3. During Phase 4, patients were assessed for impending relapse/exacerbation of psychotic symptoms. If a patient was identified with impending relapse/exacerbation of psychotic symptoms, they were withdrawn from the trial and given the opportunity to enroll into an open-label aripiprazole IM depot trial, 31-08-248. Patients that completed Phase 4 (up to and including Week 52) had the option to enroll into an open-label aripiprazole IM depot trial, 31-08-248 (NCT00731549).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 843
• Est. completion date: February 2011
• Est. primary completion date: August 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Subjects who are able to provide written informed consent and/or consent obtained from a legally acceptable representative (as required by the Institutional Review Board/Institutional Ethics Committee [IRB/IEC]), prior to the initiation of any protocol-required procedures.

• Male and female subjects 18 to 60 years of age, inclusive, at time of informed consent.

• Subjects with a current diagnosis of schizophrenia as defined by Diagnostic and Statistical Manual of Mental Disorders, 4th edition text revision (DSM-IV-TR) criteria and a history of the illness for at least 3 years prior to screening.

• Subjects who, in the investigator's judgment, require chronic treatment with an antipsychotic medication.

• Subjects able to understand the nature of the study and follow protocol requirements, including the prescribed dosage regimens, tablet ingestion, IM depot injection, discontinuation of prohibited concomitant medications; who can read and understand the written word in order to complete patient-reported outcomes measures; and who can be reliably rated on assessment scales.

Exclusion Criteria:

• Subjects with a current DSM-IV-TR diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, or amnestic or other cognitive disorders. Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.

• Subjects with schizophrenia that are considered resistant/refractory to antipsychotic treatment by history or response only to clozapine.

• Subjects with a significant risk of violent behavior or a significant risk of committing suicide based on history or investigator's judgment.

• Subjects who currently meet DSM-IV-TR criteria for substance dependence, including alcohol and benzodiazepines, but excluding caffeine and nicotine; or 2 positive drug screens for cocaine.

• Subjects who are known to be allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones; or hypersensitivity to antipsychotic agents.

• Subjects with uncontrolled thyroid function abnormalities.

• Subjects with a history of seizures, neuroleptic malignant syndrome, clinically significant tardive dyskinesia, or other medical condition that would expose them to undue risk or interfere with study assessments.

• Subjects who are involuntary incarcerated.

• Subjects who have used an investigational agent within 30 days of screening or prior participation in a clinical study with aripiprazole IM depot.

• Subjects with clinically significant abnormalities in laboratory test results, vital signs, or ECG results; and subjects hospitalized for more than 30 days in the 90 days prior to Phase 1.

• Subjects who fail to wash-out from prohibited concomitant medications, including the use of CYP2D6 or CYP3A4 inhibitors or CYP3A4 inducers, antipsychotics, antidepressants (including monoamine oxidase inhibitors [MAOI}), and mood stabilizers during screening and/or Phase 1.

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Drug:
• Aripiprazole depot
Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
• Placebo depot
Placebo depot was supplied in 400 mg lyophilized vials.

Locations

Country	Name	City	State
Argentina	Otsuka Investigational Site	Buenos Aires
Argentina	Otsuka Investigational Site	Buenos Aires
Argentina	Otsuka Investigational Site	Ciudad Autónoma de Bs. As.	Buenos Aires
Argentina	Otsuka Investigational Site	Cordoba
Argentina	Otsuka Investigational Site	La Plata	Buenos Aires
Argentina	Otsuka Investigational Site	Lanús Este	Buenos Aires
Argentina	Otsuka Investigational Site	Mendoza
Argentina	Otsuka Investigational Site	Mendoza
Argentina	Otsuka Investigational Site	Pueyrredón	Cordoba
Argentina	Otsuka Investigational Site	Rosario	Santa Fe
Bulgaria	Otsuka Investigational Site	Lovech
Bulgaria	Otsuka Investigational Site	Pleven
Bulgaria	Otsuka Investigational Site	Plovdiv
Bulgaria	Otsuka Investigational Site	Radnevo
Bulgaria	Otsuka Investigational Site	Region of Veliko Tarnovo
Bulgaria	Otsuka Investigational Site	Rousse
Bulgaria	Otsuka Investigational Site	Sofia
Bulgaria	Otsuka Investigational Site	Varna
India	Otsuka Investigational Site	Ahmedabad	Gujarat
India	Otsuka Investigational Site	Bangalore	Karnataka
India	Otsuka Investigational Site	Chennai	Tamil Nadu
India	Otsuka Investigational Site	Kanpur
India	Otsuka Investigational Site	Mangalore
India	Otsuka Investigational Site	Pune
India	Otsuka Investigational Site	Tirupati
Malaysia	Otsuka Investigational Site	Cheras	Kuala Lumpur
Malaysia	Otsuka Investigational Site	Kuala Lumpur	Wilayah Persekutuan
Malaysia	Otsuka Investigational Site	Selangor
Malaysia	Otsuka Investigational Site	Tanjong Rambutan	Perak
Mexico	Otsuka Investigational Site	Culiacan	Sinaloa
Mexico	Otsuka Investigational Site	Guadalajara	Jalisco
Mexico	Otsuka Investigational Site	Mexico	DF
Mexico	Otsuka Investigational Site	Monterrey	Nuevo León
Mexico	Otsuka Investigational Site	San Luis Potosí
Philippines	Otsuka Investigational Site	Bataan	Central Luzon
Philippines	Otsuka Investigational Site	Cebu City
Philippines	Otsuka Investigational Site	Iloilo	Western Visayas
Philippines	Otsuka Investigational Site	Mandaluyong	NCR
Philippines	Otsuka Investigational Site	Quezon City	NCR
Romania	Otsuka Investigational Site	Arad
Romania	Otsuka Investigational Site	Bucuresti
Romania	Otsuka Investigational Site	Cluj-Napoca
Romania	Otsuka Investigational Site	Craiova
Romania	Otsuka Investigational Site	Oradea
Romania	Otsuka Investigational Site	Pitesti
Russian Federation	Otsuka Investigational Site	Lipetsk
Russian Federation	Otsuka Investigational Site	Moscow
Russian Federation	Otsuka Investigational Site	Moscow
Russian Federation	Otsuka Investigational Site	Moscow
Russian Federation	Otsuka Investigational Site	Nizhny Novgorod
Russian Federation	Otsuka Investigational Site	Nizhny Novgorod
Russian Federation	Otsuka Investigational Site	Smolensk
Russian Federation	Otsuka Investigational Site	St. Petersburg
Russian Federation	Otsuka Investigational Site	St. Petersburg
Russian Federation	Otsuka Investigational Site	St. Petersburg
Serbia	Otsuka Investigational Site	Belgrade
Serbia	Otsuka Investigational Site	Kragujevac
Slovakia	Otsuka Investigational Site	Kosice
Slovakia	Otsuka Investigational Site	Liptovský Mikuláš
Slovakia	Otsuka Investigational Site	Presov
Slovakia	Otsuka Investigational Site	Rimavská Sobota
Slovakia	Otsuka Investigational Site	Svidnik
Taiwan	Otsuka Investigational Site	Changhua
Taiwan	Otsuka Investigational Site	Hualien
Taiwan	Otsuka Investigational Site	Tainan
Taiwan	Otsuka Investigational Site	Taipei
Taiwan	Otsuka Investigational Site	Taipei
United States	Otsuka Investigational Site	Albuquerque	New Mexico
United States	Otsuka Investigational Site	Altamonte Springs	Florida
United States	Otsuka Investigational Site	Anaheim	California
United States	Otsuka Investigational Site	Atlanta	Georgia
United States	Otsuka Investigational Site	Austin	Texas
United States	Otsuka Investigational Site	Baton Rouge	Louisiana
United States	Otsuka Investigational Site	Baton Rouge	Louisiana
United States	Otsuka Investigational Site	Bellevue	Washington
United States	Otsuka Investigational Site	Bothell	Washington
United States	Otsuka Investigational Site	Bradenton	Florida
United States	Otsuka Investigational Site	Buffalo	New York
United States	Otsuka Investigational Site	Cedarhurst	New York
United States	Otsuka Investigational Site	Chandler	Arizona
United States	Otsuka Investigational Site	Cleveland	Ohio
United States	Otsuka Investigational Site	Columbia	Maryland
United States	Otsuka Investigational Site	DeSoto	Texas
United States	Otsuka Investigational Site	Elmsford	New York
United States	Otsuka Investigational Site	Flowood	Mississippi
United States	Otsuka Investigational Site	Highlands Ranch	Colorado
United States	Otsuka Investigational Site	Hoffman Estates	Illinois
United States	Otsuka Investigational Site	Holliswood	New York
United States	Otsuka Investigational Site	Hollywood	Florida
United States	Otsuka Investigational Site	Jamaica	New York
United States	Otsuka Investigational Site	Lake Charles	Louisiana
United States	Otsuka Investigational Site	Maitland	Florida
United States	Otsuka Investigational Site	Memphis	Tennessee
United States	Otsuka Investigational Site	Miami	Florida
United States	Otsuka Investigational Site	Munster	Indiana
United States	Otsuka Investigational Site	National City	California
United States	Otsuka Investigational Site	New Orleans	Louisiana
United States	Otsuka Investigational Site	North Miami	Florida
United States	Otsuka Investigational Site	North Platte	Nebraska
United States	Otsuka Investigational Site	Norwalk	Connecticut
United States	Otsuka Investigational Site	Oceanside	California
United States	Otsuka Investigational Site	Oklahoma City	Oklahoma
United States	Otsuka Investigational Site	Orange City	Florida
United States	Otsuka Investigational Site	Philadelphia	Pennsylvania
United States	Otsuka Investigational Site	Richland	Washington
United States	Otsuka Investigational Site	San Diego	California
United States	Otsuka Investigational Site	Santa Ana	California
United States	Otsuka Investigational Site	St. Louis	Missouri
United States	Otsuka Investigational Site	Staten Island	New York
United States	Otsuka Investigational Site	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Otsuka Pharmaceutical Development & Commercialization, Inc.

Countries where clinical trial is conducted

United States,  Argentina,  Bulgaria,  India,  Malaysia,  Mexico,  Philippines,  Romania,  Russian Federation,  Serbia,  Slovakia,  Taiwan, 

References & Publications (1)

Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA, McQuade RD, Carson WH, Fleischhacker WW. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-contro — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to Exacerbation of Psychotic Symptoms/Impending Relapse	A patient experienced an exacerbation of psychotic symptoms/impending relapse if they met any of the following 4 criteria. 1) Clinical Global Impression of Improvement score = 5 and either an increase on any of the following Positive and Negative Syndrome Scale (PANSS) items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) to a score > 4 with an increase of = 2 on that item since randomization or an increase on any of the same PANSS items to a score > 4 and an increase of = 4 on the same combined PANSS items since randomization, 2) Hospitalization due to worsening of psychotic symptoms, 3) Clinical Global Impression of Severity of Suicide (CGI-SS) score of 4 or 5 on Part 1 and/or 6 or 7 on Part 2, or 4) Violent behavior resulting in clinically significant self-injury, injury to another person, or property damage.	Baseline of the depot maintenance phase to the end of the study (Week 52)
Secondary	Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria	This is the key secondary Outcome Measure.	Baseline of the depot maintenance phase to the end of the study (Week 52)
Secondary	Percentage of Responders	A patient was considered to be a responder if all of the following criteria were met. 1) Outpatient status, 2) PANSS total score = 80, 3) Lack of specific psychotic symptoms on the PANSS as measured by a score of = 4 on each of the following items (possible scores of 1 to 7 for each item): Conceptual disorganization, suspiciousness, hallucinatory behavior, unusual thought content, and 4) Clinical Global Impression of Severity of Illness (CGI-S) = 4 (moderately ill) and 5) CGI-SS = 2 (mildly suicidal) on Part 1 and = 5 (minimally worsened) on Part 2.	Baseline of the depot maintenance phase to the end of the study (Week 52)
Secondary	Percentage of Patients Achieving Remission	A patient was considered to have achieved remission if they had a score of = 3 on each of the following PANSS items, maintained for a period of 6 months: Delusions (P1), unusual thought content (G9), hallucinatory behavior (P3), conceptual disorganization (P2), mannerisms/posturing (G5), blunted affect (N1), social withdrawal (N4), and lack of spontaneity (N6).	Baseline of the depot maintenance phase to the end of the study (Week 52)
Secondary	Mean Change From Baseline in the PANSS Total Score	The PANSS consists of 3 subscales (Positive Subscale, 7 constructs, scores ranged from 7-49, Negative Subscale, 7 constructs, scores ranged from 7-49, General Psychopathology Subscale, 16 constructs, scores ranged from 16-112) containing a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. The PANSS total score ranged from 30-210 with a higher score indicating more severe symptoms. A negative change score indicates improvement.	Baseline of the depot maintenance phase to the end of the study (Week 52)
Secondary	Mean Change From Baseline in the Clinical Global Impression - Severity (CGI-S) Score	The severity of illness for each patient was rated using the CGI-S. To assess CGI-S, the rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. The CGI-S score ranged from 0-7 with a higher score indicating greater illness. A negative change score indicates improvement.	Baseline of the depot maintenance phase to the end of the study (Week 52)
Secondary	Mean Change From Baseline in the PANSS Positive Subscale Score	The PANSS Positive Subscale consists of 7 symptom constructs (delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility). For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Scores on each subscale ranged from 7-49 with a higher score indicating more severe symptoms. A negative change score indicates improvement.	Baseline of the depot maintenance phase to the end of the study (Week 52)
Secondary	Mean Change From Baseline in the PANSS Negative Subscale Score	The PANSS Negative Subscale consists of 7 symptom constructs (blunted affect, emotional withdrawal, poor rapport, passive pathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking). For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Scores on each subscale ranged from 7-49 with a higher score indicating more severe symptoms. A negative change score indicates improvement.	Baseline of the depot maintenance phase to the end of the study (Week 52)
Secondary	Mean Clinical Global Impression-Improvement (CGI-I) Score	The efficacy of the study medication was rated for each patient using the CGI-I scale. The rater or investigator rated the patient's total improvement whether or not it was due entirely to drug treatment. All responses were compared to the patient's condition at Baseline. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I score ranged from 0-7 with a higher score indicating less improvement/worsening.	Baseline of the depot maintenance phase to the end of the study (Week 52)
Secondary	Time to Discontinuation	Time to discontinuation was defined as the date of randomization to the date of study discontinuation.	Baseline of the depot maintenance phase to the end of the study (Week 52)